ScreenerHero

ATHEAlterity Therapeutics Limited

NAS · US · Healthcare · Biotechnology · alteritytherapeutics.com
4.670USDMkt Cap: 84.65M $P/E: —

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap84.65M $
Enterprise Value-47.41M $
Revenue (TTM)6.64M $
Gross Profit6.47M $
Net Income (TTM)-12.15M $
Revenue/Share22.80 USD
Last Price4.670 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.24
PEG—
EV/EBITDA2.70
EV/Revenue-7.14
P/S12.75
P/B0.04
EPS (TTM)-0.60
EPS (Forward)-0.89
52W Range
4.51094% of range4.680
52W High4.680 USD
52W Low4.510 USD
Profitability
Gross Margin97.55%
Oper. Margin-372.59%
EBITDA Margin-264.46%
Profit Margin-219.85%
ROE-28.65%
ROA-26.39%
Growth
Revenue Growth74.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.45M $
CapEx (TTM)—
FCF Margin-159.86%
FCF Yield-12.53%
Net Debt-49.10M $
Net Debt/EBITDA2.80
Balance Sheet
Debt/Equity0.00
Current Ratio21.98
Quick Ratio21.68
Book Value/Sh106.35 USD
Cash/Share135.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 9, 2023
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.25 USD
Upside (mean)+183.7%
Target Range10.00 USD – 16.00 USD
$10.00+183.7% to mean$16.00
# Analysts4
Ownership
Shares Out.18.13M
Float288.04K
Insiders0.00%
Institutions2.17%
Short Interest
Short Ratio1.2d
Short % Float0.12%
Short % Out.0.12%
Shares Short21.09K
Short (prev mo.)38.98K
Technical
SMA 504.832 (-3.3%)
SMA 2003.960 (+17.9%)
Beta-0.04
S&P 52W Chg19.18%
Avg Vol (30d)10.17K
Avg Vol (10d)18.05K
Technical Indicators
RSI (14)49.9
MACD-0.0378
MACD Signal-0.0522
MACD Hist.+0.0144
BB Upper4.877 USD
BB Middle4.577 USD
BB Lower4.276 USD
BB Width13.12%
ATR (14)0.2948 USD
Vol Ratio (20d)0.92x